| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1028803597 |
| P356 | DOI | 10.2165/00003495-200767020-00009 |
| P698 | PubMed publication ID | 17284090 |
| P50 | author | Lesley J Scott | Q62563724 |
| P2093 | author name string | Dene Simpson | |
| P2860 | cites work | Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans | Q46799661 |
| Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy | Q46892907 | ||
| Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. | Q46915139 | ||
| Guidelines for treatment of candidiasis | Q75213797 | ||
| Fungal infections | Q82626050 | ||
| Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P | Q24535844 | ||
| A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients | Q28189320 | ||
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial | Q28278518 | ||
| A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei | Q28379227 | ||
| Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. | Q30447051 | ||
| Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole | Q30452973 | ||
| In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs | Q30453001 | ||
| Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi | Q33188045 | ||
| Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen | Q33241227 | ||
| Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America | Q33894472 | ||
| Newer systemic antifungal agents : pharmacokinetics, safety and efficacy | Q33981062 | ||
| Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration | Q34141420 | ||
| Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases | Q34404335 | ||
| Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy | Q34430768 | ||
| Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. | Q34551726 | ||
| Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood | Q34774859 | ||
| Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole | Q34941412 | ||
| Voriconazole: in the treatment of invasive aspergillosis | Q35016972 | ||
| Voriconazole: a new triazole antifungal agent | Q35069136 | ||
| British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections | Q35101150 | ||
| Invasive oesophageal candidiasis: current and developing treatment options | Q35109119 | ||
| Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole | Q35169486 | ||
| Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis | Q35537846 | ||
| New approaches to invasive fungal infections | Q35561985 | ||
| Changing strategies for the management of invasive fungal infections | Q35678997 | ||
| Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety | Q35825582 | ||
| Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole | Q35951479 | ||
| Pseudoporphyria induced by voriconazole | Q36195606 | ||
| Antifungal combination therapy: clinical potential | Q36201569 | ||
| Caspofungin: a review of its use in the treatment of fungal infections | Q36257157 | ||
| Advances and challenges in management of invasive mycoses | Q36259905 | ||
| Successful Outcome of DisseminatedFusariumInfection with Skin Localization Treated with Voriconazole and Amphotericin B-Lipid Complex in a Patient with Acute Leukemia | Q36891747 | ||
| In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata | Q37489291 | ||
| In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies | Q37598686 | ||
| Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. | Q38970314 | ||
| In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. | Q39652771 | ||
| Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei | Q39743425 | ||
| Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani | Q40667778 | ||
| Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis | Q40667866 | ||
| Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation | Q41847739 | ||
| The pharmacokinetics and safety of intravenous voriconazole – a novel wide‐spectrum antifungal agent | Q42022417 | ||
| Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole | Q42284203 | ||
| Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. | Q42286250 | ||
| Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. | Q42561331 | ||
| Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods | Q42708807 | ||
| Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis | Q43175172 | ||
| Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis | Q43864353 | ||
| Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children | Q43989240 | ||
| Safety of voriconazole and dose individualization | Q44396667 | ||
| Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole | Q44403610 | ||
| Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections | Q44417870 | ||
| The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human | Q44447139 | ||
| Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl | Q44460408 | ||
| Voriconazole in the treatment of invasive mold infections in transplant recipients. | Q44492164 | ||
| Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients | Q44564506 | ||
| Liver failure in a child receiving highly active antiretroviral therapy and voriconazole | Q44573512 | ||
| Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience | Q44589171 | ||
| Successful treatment of pulmonary invasive aspergillosis with voriconazole in patients who failed conventional therapy | Q44620255 | ||
| Voriconazole salvage treatment of invasive candidiasis. | Q44621426 | ||
| Successful Voriconazole Therapy of Disseminated Fusarium Solani in the Brain of a Neutropenic Cancer Patient | Q44634373 | ||
| Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy | Q44711161 | ||
| Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans | Q44725080 | ||
| Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants | Q44777583 | ||
| Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients | Q44807745 | ||
| Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis | Q44818786 | ||
| Cutaneous infection by Fusarium: successful treatment with oral voriconazole | Q44852586 | ||
| In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens | Q44882934 | ||
| Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients | Q44908635 | ||
| Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient | Q44919437 | ||
| Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis | Q44925292 | ||
| Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required | Q44964107 | ||
| Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole | Q44973763 | ||
| Fusarium dimerum infection in a stem cell transplant recipient treated successfully with voriconazole. | Q45054608 | ||
| Post-antifungal effect of amphotericin B and voriconazole against Aspergillus fumigatus analysed by an automated method based on fungal CO2 production: dependence on exposure time and drug concentration | Q45096407 | ||
| Echinocandins: ask not what they can do for esophageal candidiasis--ask what studies of esophageal candidiasis can do for them | Q45097005 | ||
| Pseudoporphyria as a result of voriconazole use: a case report | Q45107364 | ||
| Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. | Q45144376 | ||
| Intravitreal voriconazole: an electroretinographic and histopathologic study | Q45144668 | ||
| Voriconazole-induced retinoid-like photosensitivity in children | Q45170996 | ||
| Toxic epidermal necrolysis as a complication of treatment with voriconazole. | Q45179002 | ||
| Effect of voriconazole on a corneal abscess caused by fusarium | Q45192114 | ||
| Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child | Q45212195 | ||
| Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients | Q45254610 | ||
| Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia | Q45268081 | ||
| Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases | Q46404978 | ||
| Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis | Q46405007 | ||
| Sinus zygomycosis in a patient receiving voriconazole prophylaxis | Q46414234 | ||
| Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. | Q46503372 | ||
| In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi | Q46595795 | ||
| Invasive Candida species infections: a 5 year population-based assessment | Q46616044 | ||
| Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin | Q46683874 | ||
| Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes | Q46686355 | ||
| Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients | Q46707138 | ||
| Breakthrough zygomycosis and voriconazole | Q46710193 | ||
| Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists | Q46711915 | ||
| P433 | issue | 2 | |
| P921 | main subject | voriconazole | Q412236 |
| invasive fungal infections | Q55022218 | ||
| P304 | page(s) | 269-298 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Voriconazole : a review of its use in the management of invasive fungal infections | |
| P478 | volume | 67 |
| Q40140821 | A Case Report of Gastrointestinal Basidiobolomycosis Treated With Voriconazole: A Rare Emerging Entity. |
| Q39048531 | An update on the safety and interactions of antifungal drugs in stem cell transplant recipients. |
| Q41519513 | Antifungal Susceptibility Testing with Etest for Candida Species Isolated from Patients with Oral Candidiasis |
| Q38101520 | Antifungal agents in current pediatric practice. |
| Q38015090 | Antifungal therapy in children: an update |
| Q34150943 | Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients |
| Q37411155 | Clinical analysis of non-AIDS patients pathologically diagnosed with pulmonary cryptococcosis |
| Q37328834 | Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis |
| Q37190801 | Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin |
| Q24317436 | Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A |
| Q36667044 | Coordinated roles of pregnane X receptor and constitutive androstane receptor in autoinduction of voriconazole metabolism in mice |
| Q95852431 | Development and in vitro Evaluation of Voriconazole Nanoparticle Formulation for Mucosal Application |
| Q43190364 | Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus |
| Q37936259 | Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies |
| Q53748960 | Enhanced skin deposition and delivery of voriconazole using ethosomal preparations. |
| Q34483712 | Evaluation of Hepatotoxicity with Off-Label Oral-Treatment Doses of Voriconazole for Invasive Fungal Infections |
| Q30223895 | Fungal infections associated with contaminated methylprednisolone in Tennessee. |
| Q40098450 | Gastro-intestinal basidiobolomycosis in a 2-year-old boy: dramatic response to potassium iodide. |
| Q33650105 | Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer |
| Q92613671 | High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness |
| Q36018595 | Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults |
| Q37071358 | In vitro and in vivo study on the effect of antifungal agents on hematopoietic cells in mice |
| Q38987096 | Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis |
| Q34960317 | Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections |
| Q34006585 | Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis |
| Q44705704 | Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience |
| Q57900034 | Mycoses and Antifungals: reviewing the basis of a current problem that still is a biotechnological target for marine products |
| Q38359303 | Nebulised liposomal amphotericin B for Aspergillus lung diseases: case series and literature review |
| Q39112946 | Nebulized Liposomal Amphotericin B for Treatment of Pulmonary Infection Caused by Hormographiella aspergillata: Case Report and Literature Review. |
| Q56518068 | Neutropenia and invasive fungal infection in patients with hematological malignancies treated with chemotherapy: a multicenter, prospective, non-interventional study in China |
| Q37579222 | New generation azole antifungals in clinical investigation |
| Q39651238 | Non-clinical safety assessment and toxicokinetics of voriconazole and anidulafungin in the juvenile rat: a combination study design in support of a Paediatric Investigation Plan |
| Q41545511 | Novel pyrazine analogs of chalcones: synthesis and evaluation of their antifungal and antimycobacterial activity. |
| Q37702237 | Pharmacoeconomics of voriconazole |
| Q40982014 | Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections |
| Q44856263 | Pharmacokinetics and distribution of voriconazole in body fluids of dogs after repeated oral dosing |
| Q44334907 | Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients |
| Q37154746 | Posaconazole : a review of its use in the prophylaxis of invasive fungal infections |
| Q43194325 | Preparation and stability of voriconazole eye drop solution |
| Q33573641 | Primary or secondary antifungal prophylaxis in patients with hematological maligancies: efficacy and damage |
| Q37263320 | Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy |
| Q37214044 | Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata |
| Q34276700 | Resistance to antifungals that target CYP51. |
| Q39215244 | Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections |
| Q38036740 | Safety and interactions of new antifungals in stem cell transplant recipients. |
| Q33741282 | Scedosporium cerebral abscesses after extra-corporeal membrane oxygenation |
| Q38516792 | Successful Treatment of Refractory Majocchi's Granuloma with Voriconazole and Review of Published Literature |
| Q33876645 | Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. |
| Q35693680 | The challenge of managing fusariosis |
| Q33499168 | The role of voriconazole in the treatment of central nervous system blastomycosis |
| Q37255172 | Treatment of invasive candidiasis in immunocompromised pediatric patients |
| Q38536076 | Update on the treatment of disseminated fusariosis: Focus on voriconazole. |
| Q53781679 | Verrucous Plaque in a Healthy Teen. |
| Q33625746 | Voriconazole associated torsades de pointes in two adult patients with haematological malignancies. |
| Q33613685 | Voriconazole pharmacokinetics in liver transplant recipients. |
| Q42275821 | Voriconazole suppresses the growth of Leishmania species in vitro |
| Q46504408 | Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results |
| Q37144791 | Voriconazole use for endemic fungal infections |
| Q35121384 | Voriconazole, an antifungal triazol that causes visual side effects, is an inhibitor of TRPM1 and TRPM3 channels |
| Q37043809 | Voriconazole-Induced Periostitis Mimicking Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation |
| Q37141191 | When primary antifungal therapy fails |
| Q83392396 | [Antifungal therapy update: new drugs and medical uses] |
Search more.